Weight loss injections are an increasingly popular way for people to manage their weight.
However, the injections' impact on reproductive health - from fertility onwards - is relatively unknown. Manufacturers currently advise that they should be stopped before people try to get pregnant, and should not be used during pregnancy or whilst breastfeeding.
Now an international study led by the University of Plymouth has examined available research to understand what science tells us to date, and use that to form a set of evidence-based guidelines for families and health professionals seeking to understand if and when incretin-based medications - such as weight loss injections - could be used safely before and after pregnancy.
The guidance covers everything from contraception (with strong encouragement for women to use reliable non-oral contraception if using tirzepatide medication) to the need to monitor intake of nutrients alongside using the injections before pregnancy.
How did the research work?
The research searched through all existing studies related to incretin-based medications - such as weight loss injections - and reproductive health. It found over 30 studies altogether, and drew on that evidence to form the basis of guidelines.
However, the low number of studies meant there were many gaps in evidence, so the study authors - with expertise stretching across all healthcare disciplines - have provided additional guidance based on their own, extensive knowledge and experience.
/University Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
